SCF ENCYCLOPEDIA ENTRY

TUBEROUS SCLEROSIS COMPLEX (TSC)

SCF MTOR PATHWAY DYSREGULATION & MULTISYSTEM HAMARTOMA FORMATION DOSSIER

I. OFFICIAL DISEASE CLASSIFICATION

II. CLINICAL DEFINITION

Tuberous Sclerosis Complex (TSC) is a multisystem genetic disorder caused by pathogenic variants in:

• TSC1 (Hamartin)
• TSC2 (Tuberin)

The disease is characterized by:

• Benign tumor formation (hamartomas)
• Epilepsy
• Autism spectrum manifestations
• Cognitive impairment
• Renal tumors
• Dermatologic lesions
• Pulmonary complications

Primary affected systems:

• Brain
• Skin
• Kidneys
• Heart
• Lungs
• Eyes

Associated conditions:

• Epilepsy
• Autism Spectrum Disorder
• Intellectual Disability

III. MAJOR CLASSIFICATIONS

A. TSC1-Associated TSC

B. TSC2-Associated TSC

C. Mosaic TSC

IV. CORE SCF ETIOPATHOGENIC THESIS

Within SCF, Tuberous Sclerosis Complex represents failure of:

• Cellular growth governance
• Nutrient-sensing regulation
• Developmental patterning
• Tissue architecture stabilization
• Neurodevelopmental synchronization

SCF interprets TSC as a chronic growth-permission syndrome whereby cellular systems lose the ability to appropriately terminate anabolic signaling.

V. BIOLOGICAL FOUNDATION

Normal TSC Complex Function

The TSC1/TSC2 complex suppresses excessive mTOR activity.

Normal biologic relationship:

$TSC1+TSC2\Rightarrow Inhibition\ of\ mTORC1$

This allows:

• Controlled cell growth
• Autophagy regulation
• Protein synthesis balance
• Tissue homeostasis

Normal mTOR Function

mTOR regulates:

• Cell growth
• Cell division
• Nutrient sensing
• Protein synthesis
• Energy allocation

Associated concept:

• mTOR Signaling

VI. GENETIC ETIOLOGY

Principal Genes

Inheritance:

VII. CORE PATHOGENESIS

Molecular Cascade

Step 1

Loss of TSC1/TSC2 activity

↓

Step 2

Constitutive activation of Rheb

↓

Step 3

Persistent activation of mTORC1

↓

Step 4

Excessive protein synthesis

↓

Step 5

Abnormal cellular growth

↓

Step 6

Hamartoma formation and organ dysfunction

Central Disease Equation

$TSC1/TSC2\ Loss\Rightarrow mTORC1\ Hyperactivation\Rightarrow Cellular\ Overgrowth$

VIII. SCF FAULT ARCHITECTURE

IX. MULTI-OMICS PATHOGENESIS

A. Genomics

Affected pathways:

• TSC signaling
• mTOR regulation
• Cell-cycle control
• Tumor suppression

B. Transcriptomics

Abnormal expression of:

• Growth genes
• Ribosomal proteins
• Metabolic regulators
• Synaptic genes

C. Proteomics

Observed abnormalities:

• Excess translation activity
• Increased anabolic proteins
• Reduced autophagic proteins
• Synaptic dysregulation proteins

D. Metabolomics

Findings include:

• Hyperanabolic state
• Nutrient-sensing dysregulation
• Mitochondrial stress
• Altered amino-acid metabolism

E. Neurodevelopmental Omics

Features:

• Cortical tubers
• Synaptic instability
• Network hyperexcitability
• Neurodevelopmental variance

X. SCF PATHOGENESIS FLOW

Stage 1 — Genetic Mutation

TSC1 or TSC2 becomes dysfunctional.

Stage 2 — Growth Regulation Failure

mTOR signaling escapes suppression.

Stage 3 — Cellular Overgrowth

Hamartomatous lesions begin forming.

Stage 4 — Organ Involvement

Brain, kidneys, skin, heart, and lungs become affected.

Stage 5 — Network Dysfunction

Neurologic and developmental complications emerge.

Stage 6 — Progressive Multisystem Disease

Chronic surveillance and treatment become necessary.

XI. SYSTEMIC CONSEQUENCES

Neurologic

• Cortical tubers
• Seizures
• Infantile spasms
• Autism spectrum manifestations
• Intellectual disability

Associated conditions:

• Infantile Spasms
• Tuberous Sclerosis–Associated Neuropsychiatric Disorders

Renal

• Angiomyolipomas
• Renal cysts
• Chronic kidney disease

Associated condition:

• Renal Angiomyolipoma

Dermatologic

Classic lesions:

• Hypomelanotic macules
• Facial angiofibromas
• Shagreen patches
• Ungual fibromas

Associated condition:

• Facial Angiofibroma

Cardiac

Most common:

• Cardiac rhabdomyomas

Associated condition:

• Cardiac Rhabdomyoma

Pulmonary

Primarily affects adult women:

• Cystic lung disease
• Progressive respiratory dysfunction

Associated condition:

• Lymphangioleiomyomatosis

XII. RHENOVA INTERPRETATION

RHENOVA interprets TSC as a biologic growth-controller failure syndrome.

Core Dynamics

• Chronic anabolic activation
• Growth-permission lock
• Resource misallocation
• Structural overexpansion
• Organ-specific network destabilization

RHENOVA Biomarkers

XIII. DBI INTERPRETATION

Within DBI, TSC represents failure of decentralized growth-governance systems.

Normal cellular governance:

• Growth authorization
• Resource allocation
• Damage repair
• Replication control
• Autophagy management

Failure results in:

• Runaway growth permissions
• Persistent anabolic signaling
• Network instability
• Tissue overexpansion

XIV. DIAGNOSTIC HALLMARKS

Growth-control principle:

$TSC1/TSC2\ Deficiency\Rightarrow mTOR\ Hyperactivation$

Cellular relationship:

$mTOR\ Hyperactivation\Rightarrow Hamartoma\ Formation$

Clinical consequence:

$Hamartoma\ Burden\Rightarrow Multisystem\ Disease$

XV. STANDARD OF CARE

Disease-Modifying Therapy

Primary targeted therapies:

• Everolimus
• Sirolimus

Epilepsy Management

• Antiseizure medications
• EEG surveillance
• Epilepsy surgery when appropriate

Particularly important therapy:

• Vigabatrin

Long-Term Surveillance

Monitoring includes:

• Brain MRI
• Kidney imaging
• Pulmonary evaluation
• Cardiac evaluation
• Neurodevelopmental assessment

XVI. SCF-PCR THERAPEUTIC ARCHITECTURE

Preventative (PCR-P)

Goals:

• Early diagnosis
• Genetic counseling
• Seizure prevention
• Organ surveillance

Curative (PCR-C)

Future objectives:

• TSC1 gene restoration
• TSC2 gene correction
• Precision mTOR normalization
• Network-level growth regulation repair

Restorative (PCR-R)

Goals:

• Preserve neurologic function
• Minimize hamartoma burden
• Restore developmental stability
• Re-establish cellular growth synchronization

XVII. ETHNOBIOPROSPECTING TARGETS

Important: No botanical intervention can replace proven mTOR-directed therapy or correct TSC mutations.

Traditional Chinese Medicine

• Scutellaria baicalensis
• Gastrodia elata

Ayurveda

• Withania somnifera
• Bacopa monnieri

Vietnamese Thuốc Nam

• Centella asiatica
• Polyscias fruticosa

XVIII. SCF API DISCOVERY TARGETS

1. TSC1 restoration therapeutics
2. TSC2 correction platforms
3. Precision mTOR regulators
4. Autophagy restoration systems
5. Neurodevelopmental stabilization therapies
6. Hamartoma-suppression technologies
7. Cellular growth-governance restoration platforms

XIX. SCF LAYMAN’S SUMMARY

Tuberous Sclerosis Complex is a genetic disorder caused by mutations in the TSC1 or TSC2 genes, which normally act as brakes on cellular growth. When these brakes fail, the mTOR pathway becomes excessively active, causing benign tumors (hamartomas) to develop throughout the body. The brain is frequently affected, leading to seizures, developmental delays, autism-spectrum features, and learning difficulties. The kidneys, skin, heart, and lungs may also be involved. SCF interprets TSC as a failure of the body’s growth-governance system, where cellular growth signals remain activated when they should be restrained.

XX. STRATEGIC RESEARCH PRIORITIES

1. TSC1/TSC2 gene-repair therapies
2. Next-generation mTOR modulators
3. Autophagy-enhancement technologies
4. Neurodevelopmental stabilization platforms
5. Precision seizure-prevention strategies
6. Organ-specific growth-control therapeutics
7. Cellular growth-governance restoration systems

MASTER REGISTRY INDEX

SCF-TSC-0001 — Tuberous Sclerosis Complex Master Registry

SCF-TSC-MTOR-0002 — mTOR Hyperactivation Layer

SCF-TSC-HAMARTIN-TUBERIN-0003 — Growth Suppression Failure Layer

SCF-TSC-HAMARTOMA-0004 — Multisystem Hamartoma Formation Layer

SCF-TSC-RHENOVA-0005 — Growth Governance Failure Layer

SCF-TSC-DBI-0006 — Distributed Cellular Control Failure Layer

SCF-TSC-PCR-0007 — Preventative–Curative–Restorative Layer